In a study of miR-4454, Kannathasan et al. found that miR-4454 as a microRNA-based treatment to silence GNL3L (a key regulator of NF-κB signaling) may significantly reduce oncogenic GNL3L/NF-kappa B signaling-dependent cell survival, making miR-4454 a candidate for the treatment of metastatic human colorectal cancer (Kannathasan et al., 2020). This evidence concerns the gene GNL3L and colorectal cancer.